Pfizer Inc. (NYSE:PFE) Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 20.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,111,179 shares of the biopharmaceutical company’s stock after selling 293,956 shares during the quarter. Sarasin & Partners LLP’s holdings in Pfizer were worth $31,091,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new stake in Pfizer in the 2nd quarter worth $25,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners purchased a new position in Pfizer in the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in Pfizer in the 4th quarter worth about $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.4 %

Shares of Pfizer stock traded down $0.41 during trading hours on Friday, hitting $28.30. The company’s stock had a trading volume of 50,332,917 shares, compared to its average volume of 37,428,500. The stock has a market cap of $160.36 billion, a price-to-earnings ratio of -471.67, a P/E/G ratio of 1.00 and a beta of 0.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.19. The firm has a fifty day moving average of $28.75 and a 200-day moving average of $27.91.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.67 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.68 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.94%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.